SLC5A2 and type 2 diabetes mellitus: The incidence of euglycemic DKA with SGLT2 inhibitors was described as 0.1%, rates ranging from 0.16 to 0.76 events per 1000 patient-years in patients with type 2 diabetes [13, 14].